This carefully curated group of stocks features promising biotech companies with valuable drug pipelines. These smaller firms could become the next targets for lucrative partnerships or acquisitions by pharmaceutical giants, similar to Glenmark's recent $2 billion deal with AbbVie.
Published on July 11
These companies could be the next Glenmark, which secured a $2 billion licensing deal with AbbVie. Even early-stage partnerships can bring substantial upfront payments, sometimes in the hundreds of millions.
Large pharmaceutical companies increasingly depend on smaller biotech firms for innovation. With patents expiring and pressure to deliver new drugs, these nimble companies with cutting-edge pipelines become valuable acquisition targets.
When acquisition offers are announced, target company stocks typically surge. By investing before a deal is announced, you position yourself to potentially benefit from the significant premiums paid in biopharma acquisitions.
Big pharma companies increasingly acquire innovation by partnering with smaller, specialized biotech firms. This creates opportunities to invest in potential acquisition targets before they receive partnership offers that can send stock prices soaring, as seen with Glenmark's nearly $2 billion AbbVie deal.
These companies are clinical-stage biopharma firms developing novel therapies in high-demand areas like oncology and rare genetic diseases. They absorb early R&D risk but offer significant upside potential if their innovative pipelines attract partnership interest from larger pharmaceutical companies.
Each company in this group has been selected for its innovative pipeline and similarity to the profile of firms that typically attract major partnership deals. They represent smaller biotech companies with valuable drug candidates that could be attractive acquisition targets for pharmaceutical giants.
The basket's total market capitalisation is 59,457.33 ($59.46B), concentrated in a few large-cap stocks that anchor most of its value. This concentration tends to reduce volatility while limiting potential for outsized short-term gains.
BBIO: $10.39B
RPRX: $21.86B
ORIC: $1.22B
Get the full story on this Basket. Read our detailed article on its risks and potential.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
+5
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
Home Depot's recent earnings beat highlights consistent consumer spending on smaller household repair and maintenance projects. This ongoing trend presents promising opportunities for various home improvement retailers and building material suppliers.
BHP Group recently posted a massive earnings beat driven by record copper profitability, allowing the miner to raise its dividend to a four-year high. This performance highlights a structural shift toward electrification metals, creating opportunities for industrial equipment suppliers and competing copper producers.
Here are a few of the assets in this group. Create an account to unlock the full list.
BRIDGEBIO PHARMA INC
BBIO
Current Price
$83.83
Its focus on developing transformative medicines for genetic diseases makes it a prime acquisition target for larger firms seeking entry into the rare...
Its focus on developing transformative medicines for genetic diseases makes it a prime acquisition target for larger firms seeking entry into the rare disease market.
ROYALTY PHARMA PLC
RPRX
Current Price
$61.63
As a buyer of biopharmaceutical royalties, Royalty Pharma directly benefits from the trend of smaller companies out-licensing successful drugs to larg...
As a buyer of biopharmaceutical royalties, Royalty Pharma directly benefits from the trend of smaller companies out-licensing successful drugs to larger ones.
SpringWorks Therapeutics Inc
SWTX
Current Price
$46.99
Its diverse pipeline targeting severe rare diseases and cancers positions it as an attractive partner for large pharma companies looking to acquire no...
Its diverse pipeline targeting severe rare diseases and cancers positions it as an attractive partner for large pharma companies looking to acquire novel assets.
Join Nemo FREE today and unlock every stock.
It only takes 60 seconds.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+274.88%
On average, analysts expect assets in this group to grow 274.88% over the next year.
12 of 14 assets in this group are rated Buy by professional analysts.
